Join us for this live national webinar designed to bridge real-world patient perspectives with the latest advances in metastatic breast cancer (MBC) care.
$2395 includes 2 years Online Access + Live Hands-On with 2 Certificates (code NN202 at checkout) ✅Taught by Two Aesthetic MD's who oversee NP's ✅Max. 4 Providers per class ✅20u BTX and 1cc Filler included ⭐2025 aesthetic-training.com Top Pick
$2395 includes 2 years Online Access + Live Hands-On with 2 Certificates (code NN200 at checkout) ✅Taught by Two Aesthetic MD's who oversee RN's ✅Max. 4 Providers per class ✅20u BTX and 1cc Filler included ⭐2025 aesthetic-training.com Top Pick
Embark on the path to become an expert injector! This program provides you with the knowledge and practical skills needed to succeed. Class size is limited to 8, ensuring you receive an individualized training environment. Models are provided.
The PREPARE Summit program, led by experts, this program emphasizes the use of validated screening tools, clinical signs and symptoms, and emerging biomarkers to differentiate normal aging from early cognitive.
$2095 includes 2 years Online Access + Live Hands-On with 2 Certificates (use NN200 at checkout) ✅Taught by Aesthetic MD who oversees NP's ✅Max. 4 Providers per class ✅Hands-On Microneedling and Real Spun PRP ⭐2025 aesthetic-training.com Top Pick
$2095 includes 2 years Online Access + Live Hands-On with 2 Certificates (use NN202 at checkout) ✅Taught by Aesthetic MD who oversees NP's ✅Max. 4 Providers per class ✅Hands-On Microneedling and Real Spun PRP ⭐2025 aesthetic-training.com Top Pick
Join us for a live webinar where expert faculty will provide actionable insights on improving patient identification and engagement for CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).
Join us for a live, interactive TheraTalk session with an expert panel of nationally recognized lipid specialists as they review the latest guideline recommendations, pivotal evidence, and evolving strategies for LDL-C management.
Platinum-resistant ovarian cancer (PROC) remains one of the most significant challenges in gynecologic oncology; however, novel antibody-drug conjugates (ADCs) and innovative investigational therapies are opening new avenues to improve outcomes.
